FDA Grants Cannabis Extract VER-01 Breakthrough Therapy Status for Pain
The FDA has awarded Breakthrough Therapy Designation to VER-01, a pharmaceutical-grade cannabis extract for chronic low back pain. This marks the first FDA breakthrough therapy cannabis designation for pain treatment, backed by Phase 3 trials showing…
Federal Marijuana reclassification could reshape medical research and cannabis industry
Federal marijuana rescheduling medical research represents a pivotal moment for cannabis medicine, potentially removing decades-old barriers to rigorous clinical studies. This policy shift could accelerate the development of evidence-based cannabis…
Federal Marijuana reclassification could reshape medical research and cannabis industry
Federal marijuana reclassification medical research changes could remove decades-old barriers to clinical trials and evidence generation. This regulatory shift may fundamentally transform how clinicians approach cannabis medicine with proper scientific…
Why Tilray and other cannabis stocks just had their best week of 2026 – MSN
✦ New CED Clinical Relevance #70Notable Clinical Interest Emerging findings or policy developments worth monitoring closely. ⚒ Cannabis News | CED Clinic CbdFda RegulationProduct AccessMarket…
DEA Reschedules FDA-Approved Marijuana Products and State-Licensed Medical Cannabis
The DEA reschedules marijuana products impacting FDA-approved and state-licensed medical cannabis. This creates distinct regulatory pathways for cannabis medicines. Patient access and insurance coverage may be influenced by these changes.
Trump Administration Moves to Reschedule Medical Marijuana | WUNC News
The 2026 medical marijuana rescheduling policy marks a significant shift in federal cannabis regulation. This change could enhance clinical research opportunities and patient access. It represents a pivotal moment for medical cannabis policy and practice.
Expanded Use of CBD in Medical Research Gets FDA Approval – KTALnews.com
FDA approval of expanded CBD research protocols marks a significant advancement in medical research. This development enhances the quality and scope of clinical evidence available for CBD. Expanded CBD research protocols will help guide better patient…
White House Schedules Additional 2026 Cannabis Enforcement Policy Meetings
The White House has scheduled more 2026 cannabis enforcement policy meetings to discuss federal regulation updates. These meetings affect patient access and clinician liability regarding cannabis products. Stakeholders should monitor these developments…
Why RFK Jr.’s firing of FDA experts likely won’t improve public trust
FDA regulation policy clinical practice is crucial for cannabis medicine oversight and patient safety. Recent leadership changes at the FDA raise concerns about regulatory consistency. Clinicians must focus on evidence-based practices amid evolving…
Therapeutic Use of Cannabis and Cannabinoids: A Comprehensive Review
This review covers therapeutic cannabinoid applications with a focus on FDA-approved uses. It highlights evidence supporting cannabinoids for nausea, appetite, and seizure disorders. Approximately 27% of adults report medical cannabis use, underscoring…